Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Atlas Data Storage | 2026 | Seed | Undisclosed | South San Francisco |
| Foghorn Therapeutics | 2026 | Post Ipo Equity | $50.0M | Cambridge |
| BIOMx | 2025 | Post Ipo Equity | $3.0M | Ness Ziona |
| Excelsior Sciences | 2025 | Series A | $70.0M | New York |
| Nuvalent | 2025 | Post Ipo Secondary | $500.0M | Cambridge |
| ADC Therapeutics | 2025 | Post Ipo Equity | $60.0M | Lausanne |
| Octave | 2025 | Grant | Undisclosed | Menlo Park |
| Valneva | 2025 | Post Ipo Debt | $215.0M | Saint-herblain |
| ARS Pharmaceuticals | 2025 | Post Ipo Debt | $100.0M | San Diego |
| Axon Therapies | 2025 | Series A | $32.0M | New York |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Atlas Data Storage | Seed | Undisclosed | South San Francisco, United States |
| 77 | Foghorn Therapeutics | Post Ipo Equity | $50.0M | Cambridge, United States |
| 78 | BIOMx | Post Ipo Equity | $3.0M | Ness Ziona, Israel |
| 79 | Excelsior Sciences | Series A | $70.0M | New York, United States |
| 80 | Nuvalent | Post Ipo Secondary | $500.0M | Cambridge, United States |
| 81 | ADC Therapeutics | Post Ipo Equity | $60.0M | Lausanne, Switzerland |
| 82 | Octave | Grant | Undisclosed | Menlo Park, United States |
| 83 | Valneva | Post Ipo Debt | $215.0M | Saint-herblain, France |
| 84 | ARS Pharmaceuticals | Post Ipo Debt | $100.0M | San Diego, United States |
| 85 | Axon Therapies | Series A | $32.0M | New York, United States |
Atlas Data Storage is an information technology company focused on data storage solutions.
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.
Axon Therapies develops a healthcare device with a neuromodulation approach to treat heart failure.
Reprieve Cardiovascular is focused on improving outcomes for patients suffering from acute decompensated heart failure.
Actio Biosciences is a research center that develops drugs for rare diseases.
NeuroFlow is a HIPAA compliant digital health platform that optimizes the way behavioral healthcare is delivered, tracked, and assessed.
Cohere Health is a SaaS company that focuses on improving the efficiency and effectiveness of healthcare delivery.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Ascertain empowers care teams with AI to reduce admin burden and streamline operations for health systems, payers & providers.
Lomond Therapeutics creates pharmacological platforms that target escape mutations.
Perceive Pharma operates as a pharmaceutical company.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Ascend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines.
Cortica provides neurological therapies for children with autism and other developmental differences.
BlinkRx is a prescription access platform that connects patients to branded medications, ensuring transparent pricing and home delivery.
Intus Care develops healthcare analytics platform to improve care and reduce hospitalizations for patients.
Nema provides comprehensive trauma care administered by PTSD-trained therapists.
Petfolk provides modern veterinary care through in-person and virtual services.
Deerfield has invested in 160 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Deerfield's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Biopharma. The firm invests across 35 different industry categories.
Among tracked funding rounds, Nuvalent received $500.0M in a Post Ipo Secondary round. Deerfield's total known invested capital is $8.0B.
Deerfield's average investment size is $78.0M across its portfolio of 160 companies.
Recent Deerfield portfolio additions include Atlas Data Storage, Foghorn Therapeutics, BIOMx, Excelsior Sciences, Nuvalent. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors